Pharmaceutics, 2023 A significant number of deaths are reported annually worldwide due to microbial and viral infections. The development of protective medical textiles for patients and healthcare professionals has attracted many researchers’ attention.
Mohamed Hamdi +3 more
doaj +1 more source
Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C [PDF]
Терапевтический архив, 2019 Aim. Evaluate efficacy and safety of a combination of direct - acting antivirals narlaprevir/ritonavir with daclatasvir in patients with viral hepatitis C. Materials and methods.
E A Klimova +11 more
doaj +1 more source
Novel 6-Aminoquinazolinone Derivatives as Potential Cross GT1-4 HCV NS5B Inhibitors
Viruses, 2022 Chronic hepatitis C virus (HCV) infections are a worldwide medical problem responsible for diverse types of liver diseases. The NS5B polymerase enzyme has become a very interesting target for the development of anti-HCV drugs owing to its fundamental ...
Tamer Nasr +7 more
doaj +1 more source
Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents [PDF]
, 2014 Hepatitis C virus (HCV) is transmitted between hepatocytes via classical cell entry but also uses direct cell-cell transfer to infect neighboring hepatocytes.
A Owsianka +72 more
core +7 more sources
Bangladesh Journal of Pharmacology, 2017 Clinical trials evaluating the safety and efficacy of daclatasvir for chronic hepatitis C virus (HCV) genotype 4 infection are scarce and yet with small sample sizes.
Hussien Ahmed +5 more
doaj +1 more source
Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world [PDF]
The Korean Journal of Internal Medicine, 2019 Background/Aims Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of
Jae Young Oh +14 more
doaj +1 more source
Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients [PDF]
International Journal of Medical Arts, 2021 Background: Chronic Hepatitis-C virus [HCV] infection is endemic in Egypt, with the highest prevalence worldwide. There are few studies on the effectiveness and safety of direct acting antivirals in treating geriatric patients with chronic HCV.
Mohamed G. Mohamed +3 more
doaj +1 more source
Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
Journal of Virus Eradication, 2016 Objectives: Novel treatments for hepatitis C demonstrate high cure rates, but current high prices can be a barrier to rapid global treatment scale-up. Generic competition can rapidly lower drug prices.
Andrew Hill +3 more
doaj +1 more source
Annals of Hepatology, 2022 Introduction and Objectives: Death due to liver damage caused by hepatitis C virus (HCV), this agent represents one of the most frequent health threats in Mexico.
K López-Riojas +7 more
doaj +1 more source
Minimum target prices for production of direct acting antivirals and associated diagnostics to combat Hepatitis C Virus [PDF]
, 2014 Combinations of direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naïve patients. Mass treatment programs to cure HCV in developing countries are only feasible if the costs of treatment and laboratory ...
Cooke, GS +6 more
core +2 more sources